Updated treatment of castration-resistant prostate cancer.
- Author:
Song XU
1
;
Zheng-Yu ZHANG
Author Information
1. Department of Urology, Nanjing General Hospital of Nanjing Military Region, Jiangsu, China.
- Publication Type:Journal Article
- MeSH:
Antineoplastic Agents;
therapeutic use;
Humans;
Male;
Neoplasm Recurrence, Local;
Orchiectomy;
Prostatic Neoplasms;
surgery;
Prostatic Neoplasms, Castration-Resistant;
drug therapy;
mortality
- From:
National Journal of Andrology
2014;20(12):1136-1140
- CountryChina
- Language:Chinese
-
Abstract:
Most prostate cancer cases ultimately relapse after a period of initial response to castration therapy and progress to intractable castration-resistant prostate cancer (CRPC). Hardly any therapeutic options currently used can improve the 2- to 3-year survival of the patient. Recently, some new drugs for the treatment of CRPC through various action mechanisms have been approved, and others are in the advanced stage of clinical trial. This review provides an overview of these new therapeutic agents.
